Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant PK/PD and Safety in Pediatric CINV
NCT01697579Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (7 arms), sponsored by Merck & Co. Primary endpoints: Maximum Concentration of Aprepitant, Time to Maximum Concentration of Aprepitant and 7 more. Started Dec 2012; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01697579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697579.